The rise of ‘generic’ biologics should mean cost savings for employer drug plans
Most of us are familiar with the difference between brand-name drugs and their generic equivalents. Basically, the generics are “bio-equivalent” to the brand names and are, for all practical purposes, the same — only cheaper.
